Test Your Biomarkers’ Post

MYTH All stomach cancers are the same, and every patient has the same treatment plan. FACT Stomach cancers are NOT all the same, and each patient’s type of stomach cancer has a unique set of biomarkers. – Biomarkers are bits of information unique to you and your cancer. Cancer cell biomarkers can be genes, gene mutations, or proteins that cause cancer cells to grow and spread to other locations. It is important to check for stomach cancer biomarkers because new drugs can potentially target them and stop cancer growth. Learn more on our site https://lnkd.in/gtA8BFbG

MYTH All stomach cancers are the same, and every patient has the same treatment plan. FACT Stomach cancers are NOT all the same, and each patient’s type of stomach cancer has a unique set of biomarkers. – Biomarkers are bits of information unique to you and your cancer. Cancer cell biomarkers can be genes, gene mutations, or proteins that cause cancer cells to grow and spread to other locations. It is important to check for stomach cancer biomarkers because new drugs can potentially target them and stop cancer growth. Click the link in our bio to learn more on our site.

Breakthrough in Breast Cancer Risk Assessment Researchers have made a significant discovery in assessing breast cancer risk for individuals with BRCA mutations. Key findings: - Normal breast tissue can harbor hidden cancer-causing genetic mutations - These mutations can be detected through genome profiling - A new "clonality score" can evaluate cancer risk in high-risk individuals Implications: - Potential for early intervention and preventive measures - Improved breast cancer risk assessment for BRCA mutation carriers - Enhanced understanding of cancer development https://lnkd.in/gRx-jPZS

https://lnkd.in/gmvZ8c4E CANCER BIOMARKERS – Co-Analysis of CTCs & ctDNA: Gaining Multi-Dimensional Insights Into Cancer Heterogeneity: Yoon-Tae Kang, PhD, Abiodun Bodunrin, PhD, and Joby Chesnick, PhD, MBA, believe co-analysis of CTC abundance and phenotypic changes together with ctDNA concentration could allow for real-time monitoring of disease progression and reoccurrence, while genetic and epigenetic changes in CTCs and ctDNA mutations over time could provide valuable insights into the effectiveness of therapeutic interventions, as the presence of different somatic mutations may indicate cancer susceptibility or resistance to certain treatments.

October is breast cancer month and yes MEN too can develop breast cancer. Even though your chance of developing male breast cancer is slim, it can be deadly—about 460 men will die from the cancer each year. While not all breast cancer in men is caused by BRCA gene mutations, it puts you at a significantly higher risk. If you have the BRCA2 gene mutation, your lifetime risk of developing breast cancer jumps to about six in 100. If you have a BRCA1 mutation, the risk is about one in 100, according to the ACS. BRCA mutations also increase the risk for other cancers, including prostate cancer and pancreatic cancer. So have you covered this on WW Day 🤔

Identifying proteomic risk factors for cancer ....................... ..........using prospective and exome analyses of 1463 circulating proteins and risk of 19 cancers in the UK Biobank Solid advancements: "In conclusion, we discovered multiple associations between blood proteins and cancer risk. Many of these were detectable more than seven years before cancer diagnosis and had concordant evidence from genetic analyses, suggesting they may have a role in cancer development. We also identified proteins that may mark early cancer processes among carriers of established cancer risk variants, which may serve as potential biomarkers for risk stratification and early diagnosis." https://lnkd.in/eHhHMqjW

What Causes Refractory Myeloma?#Car-T Refractory myeloma develops as a result of cancer cells making certain changes. The longer cancer cells live, grow, and divide, the more gene changes (mutations) they collect. Some of these mutations can help protect the cancer cells from being killed by medications. For example, some mutations may allow cancer cells to pump cancer drugs out, preventing the medication from doing its job. Additionally, myeloma cells cause bone marrow changes that make it easier for the cells to survive. By modifying their environment, the cells may be able to “hide” from cancer drugs and the immune system. As a result, myeloma becomes more difficult to treat.

September 2024 marks the Blood Cancer Awareness Month. As professionals in the health care system for tumor diagnostics, we are aware of the importance of having reliable diagnostic tools. Blood cancer is diagnosed in over 1 million patients every year and describes more than 100 different types of cancer that affect the production and function of blood cells.  With increasing knowledge of different tumor classes in blood cancer comes the demand for more specified molecular diagnostic methods. Many subtypes of blood cancer can be diagnosed by testing for certain genetic alterations. Fluorescence in situ hybridization (FISH) is one of the most reliable methods to detect such gene alterations allowing for tumor classification and individual therapy decisions.     ZytoVision’s FISH portfolio includes over 60 probes that are routinely used to aid blood cancer diagnostics all over the world.     #bloodcancer #bloodcancerawareness #ThisIsBloodCancer

Hereditary Cancer Awareness Week! 🧬 About 10% of cancers may be linked to inherited genes. Having a cancer-related gene doesn't mean that you will get #cancer, but it does raise your risk. #BRCA1/ #BRCA2 testing is useful for detecting breast and ovarian cancer risk, but multigene testing goes further. It looks at multiple genes, including BRCA1/BRCA2, to identify a wider range of hereditary cancers like colorectal and endometrial cancer. By choosing multigene testing, you and your family can get a more complete picture of your cancer risks, helping physicians create a better, personalized plan for prevention. Knowing your genetic cancer risk is important in protecting your future health. Find out who should undergo the HerediGENE® genetic test for hereditary cancer: 🔗https://lnkd.in/dQfzmANC

CAR T-cell therapies: A quick overview 🔬 CAR T-cell therapies are revolutionizing cancer treatment. By genetically modifying T cells with a chimeric antigen receptor (CAR), these therapies target specific tumor antigens with high precision. Once modified, CAR T-cells are reintroduced into the patient’s bloodstream to locate, bind to, and destroy cancer cells. This approach has made it possible to cure previously incurable cancers. Currently, six CAR T-cell therapies are approved for blood cancers. While successful, these therapies face challenges like relapse rates and limited effectiveness in solid tumors. We are addressing these issues with our iTANK platform, enhancing CAR T-cell therapies for a broader range of cancers. Find out more about CAR T-cell therapies on our website: https://lnkd.in/ee-5pT4h #CARTCellTherapy #CancerTreatment #Immunotherapy